Clinical Pharmacology & Therapeutics · 2008 · 129 citations · 24 references
MedicinePharmacokineticsPharmacologyClinical PharmacologyPharmacogeneticsPharmacogenomicsDrug DispositionInterindividual VariabilityBlood PressureCyp2d6 Drug MetabolismCyp2d6 GenotypeCyp2d6 GenotypingCyp2d6 PharmacogeneticsCytochrome P450 Genotype EffectsHeart RateInterindividual Variation
After administration of metoprolol, plasma concentrations of the drug are markedly higher in CYP2D6 poor metabolizers (PMs) than in non-PMs. In a prospective double-blind 3-month study, we investigated whether this translates into differences in metoprolol's effects after initiation of therapy. Despite administering equal doses to PMs and non-PMs, metoprolol plasma concentrations were 4.9-fold higher in the PM group. Metoprolol evoked significantly and persistently greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure in PMs than in non-PMs. It appears, therefore, that the CYP2D6 genotype contributes to interindividual differences in metoprolol response.
24